Literature DB >> 31630166

Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings.

Alyssa C Vecchio1, Christina M Marra2, Jeffrey Schouten2,3, Hongyu Jiang4, Johnstone Kumwenda5, Khuanchai Supparatpinyo6, James Hakim7, Ned Sacktor8, Thomas B Campbell9, Srikanth Tripathy10, Nagalingeswaran Kumarasamy11, Alberto La Rosa12, Breno Santos13, Marcus T Silva14, Cecilia Kanyama15, Cindy Firnhaber9, Mina C Hosseinipour15, Rosie Mngqibisa16, Colin Hall1, Paola Cinque17, Kevin Robertson1.   

Abstract

BACKGROUND: Distal sensory peripheral neuropathy (DSPN) is a complication of human immunodeficiency virus (HIV). We estimate DSPN prevalence in 7 resource-limited settings (RLSs) for combination antiretroviral therapy (cART)-naive people living with HIV (PLWH) compared with matched participants not living with HIV and in PLWH virally suppressed on 1 of 3 cART regimens.
METHODS: PLWH with a CD4+ count <300 cells/mm3 underwent standardized neurological examination and functional status assessments before and every 24 weeks after starting cART. Matched individuals not living with HIV underwent the same examinations once.Associations between covariates with DSPN at entry were assessed using the χ2 test, and virally suppressed PLWH were assessed using generalized estimating equations.
RESULTS: Before initiating cART, 21.3% of PLWH had DSPN compared with 8.5% of people not living with HIV (n = 2400; χ2(df = 1) = 96.5; P < .00001). PLWH with DSPN were more likely to report inability to work [χ2(df = 1) = 10.6; P = .001] and depression [χ2(df = 1) = 8.9; P = .003] than PLWH without DSPN. Overall prevalence of DSPN among those virally suppressed on cART decreased: 20.3%, week 48; 15.3%, week 144; and 10.3%, week 192. Incident DSPN was seen in 127 PLWH. Longitudinally, DSPN was more likely in older individuals (P < .001) and PLWH with less education (P = .03). There was no significant association between cART regimen and DSPN.
CONCLUSIONS: Although the prevalence of DSPN decreased following cART initiation in PLWH, further research could identify strategies to prevent or ameliorate residual DSPN after initiating cART in RLSs.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; antiretroviral therapy; peripheral neuropathy; resource-limited

Mesh:

Year:  2020        PMID: 31630166      PMCID: PMC7312215          DOI: 10.1093/cid/ciz745

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

1.  Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.

Authors:  K Robertson; H Jiang; J Kumwenda; K Supparatpinyo; S Evans; T B Campbell; R Price; S Tripathy; N Kumarasamy; A La Rosa; B Santos; M T Silva; S Montano; C Kanyama; S Faesen; R Murphy; C Hall; C M Marra; C Marcus; B Berzins; R Allen; M Housseinipour; F Amod; I Sanne; J Hakim; A Walawander; A Nair
Journal:  Clin Infect Dis       Date:  2012-06-01       Impact factor: 9.079

2.  Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.

Authors:  Kevin R Robertson; Bibilola Oladeji; Hongyu Jiang; Johnstone Kumwenda; Khuanchai Supparatpinyo; Thomas B Campbell; James Hakim; Srikanth Tripathy; Mina C Hosseinipour; Christina M Marra; Nagalingeswaran Kumarasamy; Scott Evans; Alyssa Vecchio; Alberto La Rosa; Breno Santos; Marcus T Silva; Sylvia Montano; Cecilia Kanyama; Cindy Firnhaber; Richard Price; Cheryl Marcus; Baida Berzins; Reena Masih; Umesh Lalloo; Ian Sanne; Sarah Yosief; Ann Walawander; Aspara Nair; Ned Sacktor; Colin Hall
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

3.  Peripheral neuropathy and quality of life of adults living with HIV/AIDS in the Rulindo district of Rwanda.

Authors:  Juvenal Biraguma; Anthea Rhoda
Journal:  SAHARA J       Date:  2012

Review 4.  Role of nutrition in HIV infection: review of evidence for more effective programming in resource-limited settings.

Authors:  Saskia de Pee; Richard D Semba
Journal:  Food Nutr Bull       Date:  2010-12       Impact factor: 2.069

Review 5.  Update of HIV-Associated Sensory Neuropathies.

Authors:  Angela Aziz-Donnelly; Taylor B Harrison
Journal:  Curr Treat Options Neurol       Date:  2017-08-31       Impact factor: 3.598

6.  Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings.

Authors:  C M Marra; P Boutin; A C Collier
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

7.  Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.

Authors:  Samantha X Y Wang; Emily L Ho; Marie Grill; Evelyn Lee; Julia Peterson; Kevin Robertson; Dietmar Fuchs; Elizabeth Sinclair; Richard W Price; Serena Spudich
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

8.  Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy.

Authors:  Ronald J Ellis; Jennifer Marquie-Beck; Patrick Delaney; Terry Alexander; David B Clifford; Justin C McArthur; David M Simpson; Christopher Ake; Ann C Collier; Benjamin B Gelman; J Allen McCutchan; Susan Morgello; Igor Grant
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

Review 9.  Peripheral neuropathy in persons with tuberculosis.

Authors:  Arnold T Mafukidze; Marianne Calnan; Jennifer Furin
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2015-12-03

10.  Neurologic signs and symptoms frequently manifest in acute HIV infection.

Authors:  Joanna Hellmuth; James L K Fletcher; Victor Valcour; Eugène Kroon; Jintanat Ananworanich; Jintana Intasan; Sukalaya Lerdlum; Jared Narvid; Mantana Pothisri; Isabel Allen; Shelly J Krebs; Bonnie Slike; Peeriya Prueksakaew; Linda L Jagodzinski; Suwanna Puttamaswin; Nittaya Phanuphak; Serena Spudich
Journal:  Neurology       Date:  2016-06-10       Impact factor: 9.910

View more
  3 in total

1.  Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV.

Authors:  Ronald J Ellis; Monica Diaz; Ned Sacktor; Christina Marra; Ann C Collier; David B Clifford; Nigel Calcutt; Jerel A Fields; Robert K Heaton; Scott L Letendre
Journal:  Ann Clin Transl Neurol       Date:  2020-07-03       Impact factor: 4.511

Review 2.  People living with HIV and the emerging field of chronic pain-what is known about epidemiology, etiology, and management.

Authors:  Deepika E Slawek
Journal:  Curr HIV/AIDS Rep       Date:  2021-05-27       Impact factor: 5.071

3.  Chronic pain in people with HIV: a common comorbidity and threat to quality of life.

Authors:  Victoria J Madden; Romy Parker; Burel R Goodin
Journal:  Pain Manag       Date:  2020-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.